TPC-003

TPC-003 is a preclinical drug candidate being developed by Tetra Pharm Technologies for the treatment of Alzheimer's disease and ulcerative colitis. As a product of Tetra Pharm's research and development pipeline, which specializes in cannabinoid-based therapeutics, TPC-003 likely leverages the company's proprietary drug delivery systems, such as the EnCaps technology, to enhance the bioavailability and targeted delivery of cannabinoid compounds. In the context of Alzheimer's disease, the candidate is expected to target neuroinflammatory pathways and provide neuroprotective effects, while in ulcerative colitis, it aims to modulate the immune response and reduce intestinal inflammation. The drug is currently in the discovery to pre-clinical stage of development.